Ind-Swift Share Price

IndSwift Limited (ISL) is an Indiabased pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical finished dosage. The products manufactured by the company include cephalosporins, quinolones, aminoglycosides, macrolides, chloramphenicol, tetracyclines, sulphonamides, antianaerobics and antifungals. The company manufactures various dosage forms, including oral solutions and suspensions dry syrups and hard gelatin capsules tablets dermatologicals comprising creams, ointments, and gels eye and ear drops and injectables. The company, through their different divisions, markets formulations focusing on the needs of various therapeutic segments, such as diabetology, cardiovascular, anesthesiology, oncology, ophthalmology, neuropsychiatry, gynecology, pediatric, ENT, surgery, internal medicine, dermatology, urology, cardiology, and dental specialty.IndSwift Limited was incorporated in June, 1986. In the year 1991, the company set up a manufacturing facility for injectables and eye/ear drops. In the year 1995, they incorporated IndSwift Laboratories Ltd for initiating a backward integration into the manufacturing of APIs and advanced intermediates.In the year 1997, the company commissioned a multipurpose plant with five independent blocks erected as per US FDA standards, designed by Quara, Switzerland. In addition, they launched a Marketing Division with the name IndSwift Health Care.In the year 2000, the company launched Super Specialty Division, which is focusing on Cardiology and Diabetology segments. In the year 2001, they launched Pioglitazone and Candesartan, in which the company is the second to launch this product in India. In addition, they launched Institution/Hospital Division.In the year 2003, the company launched another division by the name IndSwift Biosciences. They entered into formulations export to six countries and filed patent in US for Clarithromycin.In the year 2004, the company launched Mukur Division with focus on ophthalmology, neuropsychiatry and ENT. They launched Launched Nitazoxanide, an antidiarrhoeal drug, first time in India after successful clinical trials. In addition, they launched another division by the name Resurgence catering to the Anesthesiology and Oncology segments. The company opened first overseas office in New Jersey, USADuring the year 200405, the company launched combination of Nitazoxanide and Ofloxacin, with the brand name NetazoxOF, first time in Asia. They commenced commercial production in their new formulation facility at Jammu, JK. During the year 200506, the company introduced various new product ranges in the domestic market through their nine marketing divisions. The new product launches included the launch of a unique combination of the Quinoline derivative, antidiarrheal and antibacterial drug that was launched for the first time in India after completion of the successful clinical trials. They also launched the new marketing division namely Institutions Hospitals division to look after the institutional sales. During the year, the company commissioned three new state of the art finished dosages facility at Samba in Jammu Kashmir 100% EOU at Jawaharpur and an internationally benchmarked plant at Baddi in Himachal Pradesh.During the year 200607, the company developed and launched 65 new products and line extension. They launched their product in Kenya and Senegal. They also launched three new marketing division to focus on marketing of products for personal healthcare, veterinary and manufacturing and marketing of products for international companies.During the year, the company entered into licensing agreements with number of international Pharma companies for out licensing the technology of their patented products, Clarithromycin. They received approval of the Drug Authorities of Uganda and Tanzania, which will pave the way for the supply of their drugs in these countries.During the year 200708, the companys manufacturing unit at Parwanoo was upgraded as per WHO standards. The Global Business Unit (ISLGBU), commissioned in Derabassi. In August 2007, the company commissioned a manufacturing facility at the same tax exempted zone and green plains of Baddi. This facility is for soft Gelatin Encapsultation with an annual capacity of 36 crore. In December 2007, they launched their new division Diagnozis dealing in medical equipments devices. The company also launched animal health care, which is absolutely a new concept with outsourced marketing.Company launched a new marketing division NOVA with special focus on ophthalmology, ENT and Dermatology in 200910.During 201011, the Company launched six divisions viz GENERIC, ONCRIT, MEGASWIFT, GYNOSWIFT, QDEN and CARDIA SWIFT. Apart from this, it launched new product range in all the new divisions including monopolistic products. During 2012, the Company diversified into the Dairy Business by launching a new division, which marketed under the brand name All Natural.In 2021, company established a separate OTC division and launched 2 products via, Stevia and Hangover.In 202223, Company launched many new products such as Linezolid, Ticagrelor, Etoricoxib, and Diclofenac Hot gel and Four Derm ointment etc. Also , Company set up its first wholly owned subsidiary in the Republic of Kenya with the name of Indswift India Limited in May, 2022. Further, Company also launched new products like Metalazone, Lenalidomide Anhydrous and Methotrexate in the domestic market in 2024.

As of 11 Jul, 2025, Ind-Swift share price is ₹16.6. The stock opened at ₹16.8 and had closed at ₹16.7 the previous day. During today’s trading session, Ind-Swift share price moved between ₹16.33 and ₹17.40, with an average price for the day of ₹16.86. Over the last 52 weeks, the stock has recorded a low of ₹12.00 and a high of ₹34.70. In terms of performance, Ind-Swift share price has declined by 40.4% over the past six months and has declined by 14.59% over the last year.